spoke to martin rogers yesterday - excellent

I called MR yesterday at 4.30 pm. he was in the US and called back.

Nasdaq:
All is well. The SEC gives a target of 3 months. This expired 2 weeks ago. Approval may come anytime. This is frustrating but not in PRR's hands. All answeres have been submitted, including some questions about accounting treatment, as this was different in the US. When asked if the SP will crash and funding problems will eventuate if appproval is not given by SCE, MR clearly said that there is no reason why approval will not be given. In any case NASDAQ has noting to do with the product.

New Funding Arrangement:
At the Deutschebank seminar in the US, MR was introduced as the MD of the next Dendreon. Many investment banks were interested in investing in PRR. I gathered that MR is waiting for the Nasdaq listing to asess the SP (hopefully will spike) and then finalise funding deals (I read between the lines). He is happy that Springtree is gone. Funding is not a problem. Many investment banks flushed with money are interested. For them 30 or 40 mill is not much. Some of them have made heaps with Dendreon and are eager to get similar results with PRR.

Trials:
When asked why details of trials were not provided, MR noted that there were about 11 people on trial this will expand. This is not like an oil rig where regular updates can be provided. Some recruits can drop out because they do not meet the criteria. The number of people on trial and the nature of trials differ and therefore updates cannot be given. All is progresing well. Up to now results are excelent, but this cannot be defined unless a few months have passed, various tests are taken, probabilities are calculated, etc. CVAC is a non toxic treatment and has been proven. It just needs to be proven that it works in larger populations and that overall life expectancy increases. Note that with Dendreon the life expectancy increases by 3 to 4 months. So generally it is not like CVAC will show poor results and the SP will go to nil like other failed biotechs. We only need to prove that life expectancy improves for commercialisation approval to be granted. I was amazed that MR feels there is no chance of failure. He sounded convincing to me. Why would he lie.

SP Movement:
MR noted that people should take a long term perspective. He feels that in the long run, the SP should go the Dendreon way. Some people such as day traders have to sell for liquidity reasons. Prople lose patience when there is no announcement, as they are not interested in PRR and CVAC but in making/protecting money. Upon insisting on investment advice, he said that I should buy some now and some more in July before phase 3 results are announced.

Reference:
After my conversation with MR, I called my other company's MD, Andrew Mortimer of PRW which is also on the cusp of big things and discussed PRR. AM was involved in PRR in the past and he spoke highly of the company and specially about Martin Rogers.

PRR is geting big and needs its own CFO (today's announcement). In his true professional style, MR did not mention about the new CFO, when I asked whether any announcement/update was coming soon.


I hold heaps. I bought some more today before posing this message. I believe the SP will be 50 cents soon and more than a dollar after Phase 3 results. If all goes well we can expect to see $6, in couple of years similar to Dendreon's market cap at that stage.

I told MR that I will be posting on HC. He was Ok with it.

Goodluck
Brainybull

PRR, PRW, CNP: These stocks can make millionaires